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Abstract
Appropriate tyrosine kinase signaling depends on coordinated sequential coupling of protein-
protein interactions with catalytic activation. Focal adhesion kinase (FAK) integrates signals from
integrin and growth factor receptors to regulate cellular responses including cell adhesion,
migration and survival. Here, we describe crystal structures representing both autoinhibited and
active states of FAK. The inactive structure reveals a mechanism of inhibition in which the N-
terminal FERM domain directly binds the kinase domain, blocking access to the catalytic cleft and
protecting the FAK activation loop from Src phosphorylation. Additionally the FERM domain
sequesters the Tyr397 autophosphorylation and Src recruitment site, which lies in the linker
connecting the FERM and kinase domains. The active phosphorylated FAK kinase adopts a
conformation that is immune to FERM inhibition. Our biochemical and structural analysis shows
how the architecture of autoinhibited FAK orchestrates an activation sequence of FERM domain
displacement, linker autophosphorylation, Src recruitment and full catalytic activation.
INTRODUCTION
Focal adhesions are integrin-mediated points of contact between the cell surface and the
extracellular matrix. Coordinated assembly and disassembly of focal adhesions as well as
intracellular signaling from these sites modulate cell adhesion, migration, proliferation,
differentiation and survival in response to cues in the extracellular milieu (Bershadsky et al.,
2003; Ridley et al., 2003). Focal adhesion kinase (FAK, gene name PTK2) is a central node
in the signaling network emanating from focal adhesions (Mitra et al., 2005; Parsons, 2003).
FAK is at once a signaling switch and a signaling scaffold – engagement of integrins and
growth factor receptors on the cell surface induces catalytic activation of FAK, and also
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promotes its recruitment and activation of Src kinases and other signaling proteins. FAK is
ubiquitously expressed, and is required for diverse developmental processes including
neuronal pathfinding and epithelial and vascular morphogenesis (Nikolopoulos and
Giancotti, 2005; Schock and Perrimon, 2002). FAK deficient mouse embryos are not viable
due to a poorly developed vascular system (Ilic et al., 1995; Ilic et al., 2003). FAK
overexpression in invasive tumors and its probable role in metastasis have made it a target
for the development of anti-cancer drugs (Cohen and Guan, 2005a; McLean et al., 2005).
FAK and the closely related proline-rich tyrosine kinase 2 (Pyk2, also known as CAKβ)
share a domain structure that includes an N-terminal FERM (band 4.1, ezrin, radixin, moesin
homology) domain, followed by a ∼40 residue linker region, a central kinase domain, a
∼220 residue proline rich low complexity region and a C-terminal focal adhesion targeting
(FAT) domain (Figure 1A). The FAT domain consists of a four helix bundle (Arold et al.,
2002; Hayashi et al., 2002) and is critical for targeting FAK to focal adhesions via binding
to paxillin, but it is not thought to play a direct role in catalytic regulation of FAK. The
FERM domain is a 3-lobed protein interaction domain (Pearson et al., 2000) found in a
number of cytoskeletal proteins (Chishti et al., 1998). In FAK, it has been shown to bind and
inhibit the kinase domain (Cooper et al., 2003), and may mediate interaction of FAK with
the cytoplasmic regions of activating receptors including β-integrins (Guan and Shalloway,
1992; Schaller et al., 1992) and the PDGFR (Sieg et al., 2000), EGFR (Sieg et al., 2000),
EphA2 (Carter et al., 2002; Miao et al., 2000) and c-Met (Chen and Chen, 2006) growth
factor receptors. The precise mechanisms by which cell-surface receptors initiate FAK
activation are not clear, but integrin or growth factor activation induces FAK to
autophosphorylate on Tyr 397 within the linker (Schaller et al., 1994). The phosphorylated
Tyr 397 site and a nearby “PxxP”- motif recruit and activate Src via binding to its SH2 and
SH3 domains, and Src in turn phoshorylates Tyr 576 and Tyr 577 in the activation loop of
the FAK kinase (Calalb et al., 1995). The activated FAK/Src complex phosphorylates
substrates including paxillin (Schaller and Parsons, 1995) and p130cas (Tachibana et al.,
1997) and effects reorganization of the actin cytoskeleton via Rho-family GTPases (Mitra et
al., 2005).
Among the major classes of non-receptor tyrosine kinases, which are all thought to be
regulated by intramolecular domain interactions, a structural level understanding is only
available for Src (Sicheri and Kuriyan, 1997; Xu et al., 1997) and Abl (Nagar et al., 2003)
kinases, which share a related SH3-SH2-Kinase regulatory apparatus (Harrison, 2003).
Other major classes with divergent domain architectures, including ZAP-70/Syk (SH2-SH2-
Kinase domains) and Jak-family kinases (FERM-SH2-Pseudokinase-Kinase domains) in
addition to FAK, have not been previously described. In order to understand the structural
basis for FAK regulation and to elucidate general principles underlying regulation of non-
receptor kinases, we determined the structure of a large fragment of FAK, containing the
FERM and kinase domains, in an autoinhibited state. The structure reveals that the
autoinhibited assembly is stabilized through an interaction between the FERM domain and
the kinase C-lobe and we show that disruption of this interaction activates the kinase.
Strikingly, a section of the linker region that contains the autophosphorylation site Tyr397 is
positioned far from the active site between the FERM domain and the kinase N-lobe. We
demonstrate that the autoinhibited assembly indeed prevents autophosphorylation of Tyr
397, and also blocks Src phosphorylation of the activation loop. Our structural and
biochemical analysis of the FAK kinase in an active, Src-phosphorylated state shows that
once the activation loop is phosphorylated, the kinase is no longer subject to inhibition by
the FERM domain.
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Overall structure of autoinhibited FAK
We crystallized a large fragment of avian FAK containing the FERM, linker, and kinase
domains in an inactive, non-phosphorylated conformation. The 2.8Å resolution structure
reveals a compact assembly with extensive interactions among the FERM, kinase and linker
regions (Figure 1B). In this autoinhibited state, the three-lobed FERM domain bridges
between the N- and C-lobes of the kinase domain, extending across the active site cleft. The
major contact between the two domains is formed between the F2 lobe of the FERM domain
and the C-lobe of the kinase domain. A portion of the linker segment containing the Tyr 397
autophosphorylation site binds to a groove on the F1 lobe of the FERM domain, and also
makes a glancing contact with the N-terminal lobe of the kinase domain. We find the same
overall conformation in two additional crystal forms of autoinhibited FAK, confirming that
the observed domain organization is not a happenstance of crystal packing (see
supplemental Table S1 for crystallographic details).
The FERM domain exhibits the characteristic 3-lobed architecture (lobes F1, F2 and F3,
Figure 1B), and its structure is essentially the same as observed previously in our studies of
the isolated FERM domain (Ceccarelli et al., 2006) (RMSD ∼ 1.24 Å). The Tyr 397
autophosphorylation site and flanking residues in the linker form an antiparallel β-strand
interaction with the FERM F1 lobe. Strikingly, this contact positions the sidechain of Tyr
397 some 35Å away from the catalytic cleft of the kinase. The linker then extends into the
kinase N-lobe, where it is in van der Waals contact with the N-terminal end of the C-helix
(αC in Figure 1B). The amino terminal portion of the linker -- including the Src SH3
docking site -- is disordered in the present structure (residues 363−393). Interestingly,
mutation of Lys 38 in the F1 lobe has been shown to increase phosphorylation of Tyr 397
(Cohen and Guan, 2005b). This residue is near (but does not contact) the linker suggesting
the possibility that it could destabilize the linker/FERM interaction.
The kinase domain in the autoinhibited structure adopts a conformation similar to that of the
isolated kinase domain in the unphosphorylated state (Nowakowski et al., 2002) (RMSD ∼
1.49), but with a small difference in the relative orientation between the N- and C-lobes (a
counterclockwise rotation of the N-lobe of approximately 12° when viewed from above).
The staurosporine compound AFN941, a broad-spectrum protein kinase inhibitor that was
included to improve crystal quality, is bound in the active site cleft in a manner analogous to
that observed in other tyrosine kinases including Jak3 (Boggon et al., 2005) and Lck (Zhu et
al., 1999). The kinase activation loop adopts an inactive conformation in which it extends
toward the FERM domain (near Ser46 in the F1 lobe) and is then unstructured between
residues Asp 573 and Leu 584. Although the Tyr 576 and Tyr 577 phosphorylation sites in
the activation loop are not visible, they must lie in the space between the active site cleft and
the F1 and F2 lobes of the FERM domain.
Why is the autoinhibited structure downregulated, and how will release of the FERM/kinase
interface activate the kinase? The overall structure of the FERM-linker-kinase assembly
suggests multiple inhibitory mechanisms: i) the position of the FERM domain sterically
blocks access of the kinase domain to potential substrates, ii) the partially unstructured,
inactive conformation of the activation loop is not expected to support binding of peptide
substrates, and the FERM domain blocks the catalytically competent conformation of the
unphosphorylated activation loop, iii) autophosphorylation of Tyr 397 is inhibited as this
segment of the linker is incorporated into a β-sheet in the FERM domain ∼ 35Å from the
active site, and iv) Tyrosines 576 and 577 within the activation loop are “sequestered” by
the FERM domain, preventing their efficient phosphorylation by Src. We confirm the
relevance of these autoinhibitory mechanisms via comparisons with the active structure of
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the FAK kinase and via functional dissection of the FERM/kinase interface as described in
the following sections.
Structure of the active FAK kinase domain
In order to better understand FAK autoinhibition and activation, we determined the structure
of the isolated kinase domain in an active conformation with both Tyr 576 and Tyr 577
phosphorylated. The structure was determined in complex with Mg2+ and the non-
hydrolysable ATP analog AMP-PNP at 2.3 Å resolution (see Methods and supplemental
Table S1). In this structure, the activation loop adopts a conformation very different from
that in the autoinhibited structure (Figure 2A). The doubly-phosphorylated loop exhibits a β-
hairpin-like conformation similar to that seen in other active tyrosine kinases including the
insulin receptor (Hubbard, 1997), Lck (Yamaguchi and Hendrickson, 1996) and Jak3
(Boggon et al., 2005). The observed conformation of the activation loop appears to be
stabilized primarily by hydrogen bond and electrostatic interactions with the phosphate
group of pTyr 577 (Figure 2B). The sidechain and phosphate group of pTyr 576 extends into
solution. Superposition of the C-lobes of the active FAK kinase on the autoinhibited
structure reveals a similar overall structure for the kinase domain (RMSD= 1.44 Å), but a
different conformation of the activation loop past the DFG motif (Figure 2C, supplemental
Figure S1). Whereas in the autoinhibited structure residues 567−573 in the activation loop
extend toward the FERM domain and partially occlude the catalytic cleft, the activation loop
in the active kinase allows free access to the active site.
In many kinases, the C-helix is an integral regulatory component -- it pivots out of the active
site cleft in the inactive conformation, and is restored to the active position by activation
loop phosphorylation and/or appropriate protein-protein interactions (Huse and Kuriyan,
2002). In FAK, comparison of the active and autoinhibited kinases shows that the position
of the C-helix (relative to the rest of the N-lobe) does not change upon activation – it is in a
position typical of active kinases in both states (Figure 2C). Thus “C-helix displacement” is
not an element of FAK regulation. Additionally, a disulfide bond that was observed in the
previously reported structure of the unphosphorylated kinase domain (Nowakowski et al.,
2002) is not present in any of our structures, active or inactive, and is therefore unlikely to
play a role in FAK regulation.
Superposition of the active kinase domain on the inactive structure also shows that pTyr576
and Ala579 in the phosphorylated activation loop collide with the FERM domain in the
autoinhibited structure, suggesting that that an active conformation of the activation loop
and FERM domain inhibition would be mutually exclusive (Figure 2C).
Phosphorylation of the activation loop overrides FERM domain inhibition
In order to dissect the inter-related roles of FERM domain engagement and activation loop
conformation, we compared the in vitro catalytic activity of the crystallized FERM+kinase
construct with that of the isolated kinase domain. Both proteins were prepared in defined,
homogeneous phosphorylation states in which Tyrosines 576 and 577 in the activation loop
were either both unphosphorylated or both phosphorylated. This experiment was performed
using a Y397F mutant of the FERM+kinase protein to preclude any confounding effects due
to Tyr 397 phosphorylation. We find that in the absence of activation loop phosphorylation,
the FERM-containing protein is approximately five-fold less active than the isolated kinase
(Figure 3). Strikingly, phosphorylation of the activation loop by Src increases the activity of
the FERM+kinase protein more than twenty-fold, activating it to a level equivalent to that of
the isolated kinase domain in the phosphorylated state. Considering this result and the steric
incompatibility of the phosphorylated activation loop and FERM engagement, we conclude
that once the activation loop is phosphorylated, the FERM domain is no longer able to
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downregulate FAK activity in vitro. These findings suggest that in a cellular context,
dephosphorylation of the FAK activation loop will be a necessary step in restoration of the
autoinhibited state.
The conserved FERM/kinase interface inhibits FAK
There are two points of contact between the FERM and kinase domains – a glancing,
indirect contact that connects the FERM F1 lobe via the linker segment to the kinase N-lobe
and a more extensive and direct contact between the F2 lobe and the kinase C-lobe (Figures
1B, 4A and 4B). The latter buries a surface area of 649 Å2, and appears to be the major
source of stabilization for the autoinhibited assembly (Figure 4A). It is also highly
conserved across species in both FAK and the related Pyk2 families (Figures 1C, 4C).
In order to test the importance of these interactions in FAK regulation, we introduced
mutations at the FERM/kinase interface and tested their effects on FAK activation and
phosphorylation in vitro and in vivo. To disrupt the contact with the kinase C-lobe, we
mutated either the FERM F2 lobe (Y180A, M183A double mutant) or Phe 596 in the kinase
domain (F596D). In the N-lobe interface, we mutated Ser 463 in the kinase C-helix (S463Y)
(Figure 4B). We find that both the Y180A, M183A and F596D mutants have dramatically
increased kinase activity as compared with the wild-type protein in vitro (Figure 4D).
Additionally, both proteins have a larger hydrodynamic radius than the wild-type protein as
measured by size-exclusion chromatography (Figure 4E). Not unexpectedly, mutation of Ser
463 in the very modest N-lobe interface only slightly increased FAK activity (Figure 4D),
and this mutant eluted from the sizing column at a volume very close to that of the wild-type
protein (Figure 4E). We expect that the larger hydrodynamic radius of the activated mutants
reflects an “open” conformation in which the FERM domain is released entirely from the
kinase domain, but we have not ruled out the possibility of dimerization or an alternative
mode of FERM domain interaction that results in a larger hydrodynamic radius.
Mutations in the FERM/kinase interface also activate full-length FAK both in vitro and in
vivo. We studied the same mutants described above, and also an additional activated FERM
domain variant (a V196D, L197D double mutant). We transiently expressed wild-type or
mutant FAK in 293 cells and found that activating mutations lead to increased levels of
autophosphorylation on Tyr397 and Src phosphorylation on Tyr 576, 577, 861 and 925
(Figure 5A). We further assayed phosphorylation of recombinant paxillin by
immunoprecipitated FAK proteins. All of the activated mutants readily phosphorylated
paxillin, whereas the wild-type and S463Y proteins did so far less efficiently (Figure 5B).
Importantly, the activated mutants induced higher levels of cellular tyrosine
phosphorylation, and also more efficiently phosphorylated co-expressed paxillin in 293 cells
(Figures 5C and 5D). Finally, the activating mutants also abrogated the usual adhesion-
dependence of FAK activation (Figures 5E and supplemental Figure S2A). We confirmed
that FAK and paxillin phosphorylation was indeed mediated by FAK and not Src by
employing a FAK kinase dead mutant or a Src-specific kinase inhibitor (supplemental
Figures S2B and S2C). Further, we confirmed that disruption of the FERM/kinase interface
does not affect FAK localization to focal adhesions (supplemental Figure S3). These results
demonstrate that the regulatory interactions we describe here are relevant to the full-length
kinase in a cellular context.
Activating phosphorylation sites are sequestered
Because the Tyr 397 autophosphorylation site is incorporated into a β-sheet of the FERM
domain and because the FERM domain apparently blocks access of Src to the activation
loop, we sought to test whether protection of these sites from phosphorylation indeed
contributes to FAK inhibition. We compared Tyr 397 autophosphorylation of the
Lietha et al. Page 5













autoinhibited, wild-type protein with that of the mutants that release the FERM/kinase
interface (Figure 6A). In the activated mutants we expect an increase in autophosphorylation
for two reasons – loss of repression of the kinase domain and also exposure of the Tyr 397
phosphorylation site. To distinguish between these effects, we included a substrate in which
the Tyr 397 site is fully exposed as an internal control (F-L, which contains the FERM and
linker regions of FAK, residues 31−405). We find that both the F596D and Y180A, M183A
FERM+kinase mutants autophosphorylate their Tyr 397 site as efficiently as they
phosphorylate the exposed Y397 in the control substrate (Figure 6A). In contrast, in the
inhibited FERM+kinase proteins (wt and S463Y) autophosphorylation was markedly less
efficient than Tyr 397 phosphorylation of the control substrate. Hence, we conclude that Tyr
397, as positioned in autoinhibited FAK, is indeed protected from autophosphorylation, and
that this protection is lost when the FERM domain is released from the kinase. It remains
unclear whether physiologically relevant autophosphorylation of Tyr 397 occurs in cis, in
trans, or by both mechanisms, but kinase-inactive FAK can clearly be transphosphorylated
on Tyr 397 in vivo (Leu et al., 2002; Toutant et al., 2002; Sieg et al., 2000). In vitro, we find
that Tyr 397 phosphorylation can occur both in cis and trans (Supplemental Figure S4). In
any case, our structural and biochemical results show that incorporation of the Tyr 397 site
as a β-strand in the FERM F1 lobe does indeed protect it from autophosphorylation, whether
it occurs in cis or trans.
We also compared the ability of Src to phosphorylate the activation loop of wild-type versus
mutant FAK. Both the F596D and Y180A, M183A proteins were more rapidly
phosphorylated on tyrosines 576 and 577 by Src in vitro (Figures 6B and 6C), although the
in vitro effect is not as striking as that observed in 293 cells (Figures 5A). The increased
levels of FAK phosphorylation on Tyr 576, 577, 861 and 925 observed in 293 cells (Figure
5A) is likely due both to exposure of the activation loop in the active state (as demonstrated
above in vitro), and to enhanced recruitment and activation of Src kinases to the Tyr 397
autophosphorylation site (supplemental Figure S2D).
DISCUSSION
To a remarkable extent, the logic of FAK signaling is encoded in the structure of the
autoinhibited enzyme. The architecture of autoinhibited FAK appears to have evolved to
enforce orderly, sequential activation in response to receptor engagement (Figure 7). In the
autoinhibited state, the kinase is locked in an inactive conformation, and the activating
phosphorylation sites in both the linker and the activation loop are sequestered. Release of
the FERM domain would appear to be required to allow autophosphorylation of Tyr 397 and
subsequent steps in activation. In analogy with Src-family kinases, which are activated by
displacement of their SH3 and/or SH2 domains (Moarefi et al., 1997), we propose that
FERM domain displacement is a key initial step in FAK activation. In this regard, a
conserved basic patch on the F2 lobe of the FERM domain that is immediately adjacent to
the site of contact with the kinase domain has been shown to be important for FAK
activation (Chen and Chen, 2006;Dunty et al., 2004). It is tempting to speculate that this site
could represent an initial site of docking for an activating protein, which might then directly
disrupt the FERM/kinase interface to activate FAK. Precisely how integrin or growth factor
engagement couples to FAK activation, and whether the coupling is direct (for example, via
integrin cytoplasmic tails) or involves additional proteins, will require further investigation.
Irrespective of the mechanism of its displacement, once the FERM domain is released, Tyr
397 is rapidly autophosphorylated and the activation loop is exposed for Src
phosphorylation, indicative of a cooperative “disassembly” of interactions among the
FERM, linker and kinase regions. Subsequent Src recruitment to the Tyr 397 site and
phosphorylation of the activation loop yield the fully active FAK enzyme.
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Comparison of FAK and Src reveals marked differences in their autoinhibitory mechanisms,
but also fundamental similarities. In Src kinases, the SH3 and SH2 domains assemble on the
“back” of the kinase domain, opposite the catalytic cleft, and inactivate the kinase domain
indirectly by stabilizing an inactive conformation in which the C-helix is displaced from the
active site (see Boggon and Eck, 2004; Sicheri and Kuriyan, 1997 for review). In contrast,
the FAK FERM domain directly blocks the catalytic cleft and the overall conformation of
the FAK kinase is remarkably similar in the autoinhibited and active conformations.
Although Src is fully activated by autophosphorylation, FAK requires partnership with Src
to achieve full catalytic activity. Despite their very different domain architectures and
mechanisms of kinase inhibition, Src and FAK do share similar features that are
fundamental to their function. In both, linker segments that connect the regulatory and
kinase domains are used to stabilize the autoinhibited assembly, in addition to direct
contacts between the regulatory and catalytic domains. Furthermore, in both kinases the
activating phosphorylation sites are sequestered in the inactive conformations, and
appropriate interactions with the regulatory domains are expected to disassemble the
autoinhibitory interactions to expose these sites for phosphorylation. These similarities in
Src and FAK may represent underlying “design principles” in tyrosine kinase signal
transduction, as it is likely that they evolved independently in both kinases.
EXPERIMENTAL PROCEDURES
Protein expression and crystallization
Avian FAK containing the FERM and kinase domains (wt and mutant FAK31−686) or only
the kinase domain (FAK411−686) were expressed in insect Hifive™ cells (Invitrogen) using
the baculovirus expression system. The FERM domain was expressed and purified as
described in (Ceccarelli et al., 2006). FERM+kinase proteins (expressed as GST fusions),
were initially purified by affinity purification on glutathione sepharose beads (GE
Healthcare). After TEV cleavage (to remove GST) proteins were further purified by anion
exchange (MonoQ, GE Healthcare) and size exclusion (Superdex200, GE Healthcare)
chromatography. Purified autoinhibited FERM+kinase was concentrated to approximately
10 mg/ml in 20 mM Tris pH 8.0, 200 mM NaCl, 5% Glycerol and 2 mM TCEP for
crystallization. Optimal crystallization was performed in hanging drops by mixing the
protein with an equal volume of 13% PEG10K, 250 mM NaCl, 100 mM Tris pH 8.5, 10 mM
TCEP and 0.2 volume of a 1mg/μl aqueous suspension of AFN941 (Novartis). Crystals were
flash-frozen in liquid nitrogen after brief soaking in precipitant solution containing
additionally 25% ethylene glycol (EG) as cryoprotectant. The FAK kinase domain
(expressed with 6xhis-tag) was initially purified on Ni sepharose beads (GE Healthcare).
Subsequently, the his-tag was removed with TEV protease. Further purification was carried
out by cation exchange (MonoS, GE Healthcare) and size exclusion (Superdex200)
chromatography. The purified FAK kinase domain was incubated for 6h at RT with human
Src (containing SH3, SH2 and kinase domains and a phosphorylated Tyr 416) at a molar
Src:FAK ratio of 1:50. Phosphorylation on Tyr 576 and Tyr 577 was monitored with
specific anti-pTyr antibodies (Biosource) and unphosphorylated protein was removed by
cation exchange chromatography (MonoS). Phosphorylated kinase was further purified and
buffer exchanged by size exclusion and concentrated to 4 mg/ml in 20 mM HEPES pH 7.0,
150 mM NaCl, 5% Glycerol and 2 mM TCEP. Crystallization was performed by pre-
incubating the protein with 2 mM AMP-PNP and 4 mM MgCl2 for 1h at 4°C before setting
up hanging drops with equal volume of 26% PEG4K, 200 mM LiSO4, 100 mM Tris pH 8.5,
10 mM TCEP. Crystals were flash-frozen in precipitant containing 18% EG.
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Data collection and structure determination
Data was collected at beamline 24-ID (NE-CAT) at the Advanced Photon Source (Argonne
National Laboratory) and beamline X29A at the National Synchrotron Light Source
(Brookhaven National Laboratory). Data was processed with HKL2000 (Otwinowski and
Minor, 1997) and yielded the following space groups and cell parameters: C212121, a=67.5,
b=91.3, c=250.7 Å for FERM+kinase crystals and P212121, a=44.3, b=71.8, c=86.9 Å for
active kinase crystals. Phases were calculated using the molecular replacement program
PHASER (Storoni et al., 2004), using the FAK FERM (2AEH) (Ceccarelli et al., 2006) and/
or the kinase domain (1MP8) (Nowakowski et al., 2002) as molecular search probes. Both
structures contained one molecule in the asymmetric unit cell (52.1 % solvent, VM=2.57 Å3/
Da, (Matthews, 1968) for the FERM+kinase structure and 44.9 % solvent, VM=2.23 Å3/Da
for the active kinase structure). Refinement was performed using the program Refmac
(Murshudov et al., 1997), manual rebuilding was carried out with the programs O (Jones et
al., 1991) and Coot (Emsley and Cowtan, 2004). Final R-factors obtained were 21.7/27.4
(Rwork/Rfree) for the FERM+kinase structure and 21.4/26.3 for the active kinase structure.
Due to disorder residues 31−34, 363−393, 574−583 were not included in the final FERM
+kinase structure. For a complete summary of data collection and refinement parameters see
supplemental Table S1.
In vitro kinase assays
Kinase assays were essentially performed as described in (LaFevre-Bernt et al., 1998). In
brief, 1 μM kinase was added to a reaction mixture containing 20 mM HEPES pH 7.0, 150
mM NaCl, 1mM TCEP, 10mM MgCl2, 100 mM phosphoenolpyruvate, 0.28 mM NADH,
0.08 units/μl pyruvate kinase, 0.1 units/μl lactate dehydrogenase, 100 μM E4Y (as polyGlu-
Tyr, 4:1 Glu:Tyr, Sigma) and reactions were initiated by addition of 0.5 mM ATP. NADH
depletion (which is coupled to the rate of the kinase reaction) was monitored by absorbance
at 340 nm using a Spectra MAX Plus spectrometer (Molecular Devices). For assaying
activation loop-phosphorylated states of the FAK kinase or FERM+kinase, proteins were
incubated for 6h at RT with human Src (containing SH3, SH2 and kinase domains) at a
molar Src:FAK ratio of 1:50. Phosphorylation on Tyr 576 and Tyr 577 was monitored with
specific anti-pTyr antibodies (Biosource) and unphosphorylated protein and Src was
removed by subsequent ion exchange and size exclusion chromatography.
Size exclusion chromatography
75 μg of wt or mutant FERM+kinase proteins were injected onto a PC3.2/30 Superdex 200
(column volume = 2.4 ml) and eluting proteins were detected by absorption at 280 nm.
Stokes radii were calculated via elution volumes of Catalase, Aldolase, BSA, Ovalbumin,
Chymotrypsinogen and Ribonuclease (Siegel and Monty, 1966).
Auto and Src phosphorylation
FERM+kinase proteins as expressed in insect cells were partially phosphorylated on Y397.
Therefore, proteins were first dephosphorylated for 4 h at RT with CD45 phosphatase at
molar CD45:FAK ratio of 1:20 molar. Dephosphorylation was monitored by Western
blotting using a specific anti-pTyr 397 antibody (Biosource). Autophosphorylation reactions
were performed at RT with 1 μM dephosphorylated FERM+kinase protein (FAK31−686 wt
or mutant) and 1 μM mutant FERM+linker protein (FAK31−405 Y180A, M183A) in 20
mM Tris pH 8.0, 150 mM NaCl, 5% Glycerol, 1 mM TCEP, 1 mM sodium vanadate, 2 mM
ATP and 4 mM MgCl2. For Src phosphorylation reactions 2 μM FERM+kinase protein, 0.2
μM human Src (SH3+SH2+kinase) and otherwise identical conditions as for
autophosphorylation reactions were used. Equal amounts were removed at time points
indicated in Figure 6 and analyzed by Western blotting using a specific anti-pTyr 397
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antibody for autophosphorylation or anti-pTyr 576 and anti-pTyr 577 antibodies for Src
phosphorylation reactions (Biosource).
Analysis of FAK in HEK293 cells
For expression of full-length FAK in cells, mutations were engineered into pcDNA3.1-FAK
constructs. The avian paxillin cDNA was subcloned into pcDNA3−1 for transient
expression. HEK 293 cells were maintained in Dulbecco’s modified Eagle’s medium/Ham’s
F-12 medium containing 10% fetal bovine serum. Cells were transfected using
Lipofectamine Plus according to the manufacturer’s recommended protocol (Invitrogen).
Cells were lysed 24 hours post transfection using modified RIPA buffer (Reynolds et al.,
1989). Phosphorylation was examined by Western blotting cell lysates using phosho-specific
antibodies (anti pY925 antibody was obtained from Santa Cruz, all others from Biosource).
For immune complex kinase assays, FAK was immunoprecipitated using the BC4
polyclonal antiserum and the immune complex incubated with 2 μg of GST-paxillin-N-C3
for 10 minutes using previously described kinase reaction conditions (Lyons et al., 2001).
The reaction was terminated by the addition of sample buffer and phosphorylation of
paxillin examined by Western blotting with phospho-specific antibodies (Biosource) or the
4G10 phosphotyrosine antibody (UBI). FAK was detected by Western blotting using the
4.47 antibody (UBI). A polyclonal antibody (Thomas et al., 1999) or commercially available
monoclonal antibody (BD Transduction Labs) was used for paxillin blotting. For detection
of adhesion dependent FAK phosphorylation wt or mutant full-length FAK was transiently
expressed in FAK null fibroblasts. In some experiments, cells were taken into suspension by
trypsinization and incubated in suspension at 37°C for 1 hour. The cells were collected by
centrifugation and lysed in modified RIPA buffer. FAK was immunoprecipitated using BC4
and analyzed by Western blotting using the 4G10 phosphotyrosine antibody (UBI).
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Figure 1. Structure of autoinhibited FAK
(A) Domain structure of FAK. Key tyrosine phosphorylation sites are indicated. (B) Overall
structure of autoinhibited FAK including the FERM, linker, and kinase regions. In the
autoinhibited state, the FERM domain (blue ribbon representation) binds the kinase domain
(red), primarily through an interaction between the FERM F2 lobe and the kinase C-lobe. A
section of the linker that contains the autophosphorylation site Tyr 397 (yellow) is located
between the FERM F1 lobe and the kinase N-lobe. The FERM domain also blocks access to
the active site cleft and to the kinase activation loop (A-loop, green). Disordered segments
are indicated as dashed lines. The staurosporine analogue AFN941 is bound to the active site
of the kinase and is shown in stick representation. (C) Sequence alignment of the FERM,
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linker and kinase regions of avian FAK (cFAK1), human FAK (hFAK1) and human Pyk2
(hPyk2). cFAK1 shares 94% sequence identity with hFAK1, and hFAK1 43% with hPyk2.
Secondary structure elements are indicated and the sequence is shaded to correspond to the
colors in panel b. Residues involved in the FERM F2 lobe/kinase C-lobe interaction are
indicated by an asterisk and regulatory tyrosines are colored magenta.
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Figure 2. Structure of the active kinase domain of FAK
(A) The structure of the FAK kinase domain phosphorylated by Src is shown in ribbon
representation (green) with the activation loop in blue. The side chains of phosphotyrosines
576 and 577 and AMP-PNP, which is bound to the active site, are shown in stick
representation. A Mg2+ ion at the active site is shown as a yellow sphere. (B) Close up view
of the activation loop with the side chains of pY576, pY577, R569, R545 and main chains of
A579 and S580 shown in stick representation. A network of hydrogen bonds (orange dashed
lines) involving the phosphate group of pY577 stabilizes the conformation of the activation
loop. (C) Superposition of active and inactive FAK kinases. The autoinhibited structure is
shown with the FERM domain as a surface representation (light blue), and the linker and
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kinase domains in a ribbon representation colored yellow and red, respectively. The
structure of the active kinase domain (green ribbon and blue activation loop) is
superimposed based on the kinase C-lobes. The side chain of pY576 and the main chain
carbonyl of A579 in the active kinase (both residues are shown in space filling
representations) clash with the FERM domain in the autoinhibited structure.
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Figure 3. Phosphorylation of the activation loop overrides FERM domain inhibition
The in vitro kinase activity of the FAK kinase (FAK411−686) and single-chain FERM
+kinase (FAK31−686) proteins is plotted for proteins that are unphosphorylated (n) or
phosphorylated on Y576 and Y577 (y). Phosphorylated proteins were obtained by treatment
with Src and subsequent repurification of phosphorylated FAK proteins. Note the reduced
activity of the FERM+kinase protein compared to that of the isolated kinase domain prior to
Src phosphorylation. Phosphorylation of the FERM+kinase protein by Src on Tyr 576 and
Tyr 577 (shown for Y397F mutant, see text) yields an activity equal to that of the isolated
kinase domain in the phosphorylated state.
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Figure 4. The FERM/kinase interface inhibits FAK
(A) Detailed view of the interaction between the FERM F2 lobe and the kinase C-lobe.
Sidechains that participate in the interaction are shown in stick form and are labeled. At the
center of the interface F596 on the kinase domain inserts into a hydrophobic pocket on the
FERM domain formed by Y180, M183, V196, L197. The periphery of the interaction is
predominantly polar. Interdomain hydrogen bonds are shown as yellow dashed lines. (B)
Detailed view of the linker region, which forms a b-sheet interaction with the FERM F1 lobe
and contacts the kinase N-lobe. Side chains of the autophosphorylation site Y397 and
residues at the linker/kinase contact point are shown. (C) Surface representation of separated
FERM (right), linker (center) and kinase (left) domains colored according to sequence
Lietha et al. Page 18













conservation. Viewing angles are indicated relative to Figure 1B. Conservation is indicated
with a color scale from red (most highly conserved) to green (most variable). Note that the
interacting surfaces of the FERM F2 lobe and kinase domain are highly conserved.
Additionally, a patch of residues at the bottom of the F2 lobe (a potential binding site for a
competitive activator, see text) and Trp266 and surrounding residues on the FERM F3 lobe
are also highly conserved. Interestingly, Trp 266 and adjacent residues on the FERM domain
form the same two-fold symmetric “dimer” interaction in every crystal structure containing
the FERM domain, even though these FAK proteins appear to be monomeric in solution.
The analysis was performed with ClustalW (Chenna et al., 2003) and ConSurf (Glaser et al.,
2003) servers, and the figure was generated with Pymol (DeLano, 2002). (D) In vitro kinase
activity of purified wt and mutant FERM+kinase proteins are plotted as negative slopes of
NADH depletion (see methods). Disruption of the FERM F2 lobe/kinase C-lobe interface
(Y180A, M183A and F596D mutations) activates the autoinhibited form of FAK. (E) Size
exclusion chromatography of purified wild-type and mutant single-chain FERM+kinase
proteins. Stokes radii were calculated by comparison with standards (Catalase, Aldolase,
BSA, Ovalbumin, Chymotrypsinogen and Ribonuclease)(Siegel and Monty, 1966).
Mutations that activate FAK result in a larger stokes radius, indicating an ‘open’
conformation, compared to the ‘closed’ autoinhibited form.
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Figure 5. Analysis of wild type and mutant FAK in HEK 293 cells
Mutations were introduced into full-length FAK to disrupt the interaction of the FERM F2
lobe with the kinase C-lobe (Y180A, M183A and V196D, L197D on the FERM domain and
F596D on the kinase domain) or to disrupt the contact of the linker with the kinase N-lobe
(S463Y). (A) Full-length wild-type or mutant FAK proteins were transiently expressed in
HEK 293 cells and cell lysates were analyzed by Western blotting with the indicated
phospho-specific antibodies or with the 4.47anti-FAK antibody. (B) In vitro kinase assay for
paxillin phosphorylation. Wild type and mutant full-length FAK proteins were
immunoprecipitated from HEK 293 lysates using BC4. The immune complex was incubated
in a kinase assay utilizing recombinant GST-paxillin-N-C3 as an exogenous substrate
(Lyons et al., 2001). Phosphorylation of paxillin was detected using the phosphospecific
antibodies pY31 and pY118, as well as the 4G10 phosphotyrosine antibody. Equal amounts
of substrate were verified by blotting for paxillin using a polyclonal antiserum. Equal
recovery of FAK proteins in the immune complex was verified by blotting for FAK. (C)
HEK 293 cells transiently expressing FAK proteins were lysed and analyzed for cellular
phosphotyrosine by Western blotting cell lysates with 4G10. (D) Paxillin and FAK were
transiently co-expressed in HEK 293 cells and paxillin phosphorylation analyzed by
Western blotting lysates using the pY31 antibody (upper panel). Lysates were blotted for
paxillin using a monoclonal antibody as a loading control (middle panel) and for FAK to
verify comparable expression of the wild type and mutant FAK proteins (bottom panel). (E)
Wild type or mutant full-length FAK was transiently expressed in FAK null cells and
adherent cells (Ad) or cells incubated in suspension at 37°C for 1 hour (sus) were lysed.
FAK was immunoprecipitated using BC4 and the immune complexes analyzed by Western
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blotting for phosphotyrosine using 4G10 (top panel). Equal amounts of FAK in the immune
complexes were verified by blotting for FAK (bottom panel).
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Figure 6. Tyrosine phosphorylation sites are protected in autoinhibited FAK
(A) Time course of autophosphorylation at Tyr 397 was carried out for wild type and mutant
purified single-chain FERM+kinase proteins (upper bands, labeled F-L-K for FERM-
Linker-Kinase). FERM+linker protein (Y180A, M183A mutant), which has Y397 exposed,
was included in the reactions as a control substrate (lower bands, labeled F-L for FERM-
Linker). Tyr 397 phosphorylation was monitored by Western blotting using a specific anti-
pY397 antibody (left panels). As loading controls equivalent gels were stained by
Coomassie (right panels). Note that autoinhibited FERM+kinase protein (wt and S463Y
mutant) autophosphorylate on Y397 much less efficiently than they phosphorylate Y397 of
the control substrate, but that this discrimination is lost on the ‘open’ mutants (Y180A,
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M183A and F596D), which autophosphorylate as rapidly as they phosphorylate the control
substrate. Also, note the overall increase in phosphorylation in the open mutants, consistent
with their increased catalytic activity (as shown in Figure 4C). (B) and (C) Time course of
Src phosphorylation of wt and mutant FERM+kinase on Tyr 576 and Tyr 577.
Phosphorylation was monitored by Western blotting using specific anitibodies against
pY576 (b, left panels) or pY577 (c, left panels) and equivalent gels were Coomassie stained
as loading controls (right panels). Note that Src phosphorylation of the activation loop
tyrosines is diminished in the intact, autoinhibited protein.
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Figure 7. Schematic of autoinhibited FAK and a sequential model of activation
In the inactive state (left), the FERM domain blocks the kinase active site and sequesters the
Tyr 397 and activation loop phosphorylation sites. Although not observed in the present
structure, we indicate the docking of the PxxP motif in the linker to the F3 lobe of the
FERM domain based on previous work (Ceccarelli et al., 2006). We propose that FAK
activation will be initiated by displacement of the FERM domain by competitive binding of
an activating protein (orange star) to the FERM F2 surface. Such interactions have not been
structurally characterized, but candidate activating proteins include the cytoplasmic regions
of b-integrins or growth factor receptors EGFR, PDGFR, c-Met or EphA2. Disassembly of
the autoinhibited conformation allows rapid autophosphorylation of the linker residue Tyr
397, and exposes the Src docking sites in the linker (center panel). In a subsequent step, Src
is recruited and activated via SH2 binding to pTyr 397 and SH3 binding to the PxxP
sequence in the linker region. Localized Src then phosphorylates the activation loop residues
Tyr 576 and Tyr 577 of FAK (right panel). Phosphorylation of the activation loop yields full
catalytic activity, and even in the event of activator dissociation will not allow kinase
inhibition by the FERM domain. Note that for simplicity we have depicted FAK
autophosphorylation in cis, it may, however, also occur in trans.
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